Patent 8106170 was granted and assigned to Crucell on January, 2012 by the United States Patent and Trademark Office.
The present invention provides compositions of binding molecules specifically binding to a coronavirus such as SARS-CoV and capable of neutralizing an infection caused by the virus. The compositions are suitable for diagnosing, preventing and/or treating a condition resulting from a coronavirus such as SARS-CoV.